Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Rating of “Moderate Buy” by Analysts

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have earned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $53.30.

ZLAB has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, October 8th. Jefferies Financial Group raised Zai Lab to a “strong-buy” rating in a research note on Monday. Finally, UBS Group started coverage on Zai Lab in a research note on Wednesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company.

Zai Lab Stock Performance

ZLAB stock opened at $18.91 on Friday. The company has a market capitalization of $2.12 billion, a PE ratio of -9.70 and a beta of 0.83. Zai Lab has a one year low of $16.82 and a one year high of $44.34. The company’s 50 day moving average price is $18.95 and its two-hundred day moving average price is $27.64.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Thursday, November 6th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05). The business had revenue of $116.10 million for the quarter, compared to the consensus estimate of $150.24 million. Zai Lab had a negative net margin of 46.83% and a negative return on equity of 25.83%. On average, research analysts predict that Zai Lab will post -2.58 EPS for the current year.

Insiders Place Their Bets

In other Zai Lab news, insider Rafael Amado sold 10,787 shares of the firm’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $17.43, for a total value of $188,017.41. Following the sale, the insider owned 52,391 shares of the company’s stock, valued at $913,175.13. This trade represents a 17.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.96% of the stock is owned by insiders.

Institutional Trading of Zai Lab

Large investors have recently modified their holdings of the business. SG Americas Securities LLC lifted its position in Zai Lab by 6.6% during the fourth quarter. SG Americas Securities LLC now owns 10,396 shares of the company’s stock valued at $183,000 after buying an additional 642 shares during the period. Royal Bank of Canada increased its stake in shares of Zai Lab by 214.3% in the 1st quarter. Royal Bank of Canada now owns 13,771 shares of the company’s stock worth $498,000 after acquiring an additional 9,390 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Zai Lab during the 1st quarter valued at about $1,073,000. 41.65% of the stock is owned by institutional investors.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.